NEW YORK – HTG Molecular Diagnostics plans to use its newly developed whole-transcriptome gene expression profiling platform, internally called WTTx, to develop oncology assays as well as tests for autoimmune disorders and infectious diseases.
The Tucson, Arizona-based firm expects to launch an early-access program by the end of the year, followed by a full commercial release of the platform in mid-2021.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.